Lisanti Capital Growth LLC Has $3.61 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Lisanti Capital Growth LLC decreased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 27.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,180 shares of the company's stock after selling 26,755 shares during the period. Lisanti Capital Growth LLC owned approximately 0.18% of Tarsus Pharmaceuticals worth $3,605,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $25,000. GF Fund Management CO. LTD. acquired a new position in Tarsus Pharmaceuticals in the fourth quarter worth approximately $44,000. Quarry LP bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $166,000. HighTower Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $207,000. Finally, Summit Investment Advisors Inc. boosted its position in Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after purchasing an additional 244 shares during the period. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Price Performance

TARS traded up $0.46 during trading on Wednesday, hitting $40.45. The company's stock had a trading volume of 413,304 shares, compared to its average volume of 687,543. The company has a quick ratio of 5.54, a current ratio of 5.57 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -14.82 and a beta of 0.80. The firm's 50 day moving average price is $43.89 and its two-hundred day moving average price is $47.72. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%. Sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TARS shares. HC Wainwright raised Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target on the stock in a research report on Tuesday, May 27th. Guggenheim upped their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price target on the stock. Finally, The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research report on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.